Managing enlarged prostate in primary care

International Journal of Clinical Practice

Volumn 60, Issue 12, 2006, Pages 1609-1615

  Naslund, Michael J ^a,d   Costa, F J ^b   Miner, M M ^c  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c BROWN UNIVERSITY   (United States)

^d NONE   (United States)

Author keywords

Benign prostatic hyperplasia; Diagnosis; Enlarged prostate; Lower urinary tract symptoms; Primary care; Treatment

Indexed keywords

ALFUZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; DUTASTERIDE; FINASTERIDE; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMSULOSIN; TERAZOSIN;

ASTHENIA; CANCER PREVENTION; CLINICAL TRIAL; DIZZINESS; DYSPNEA; EJACULATION DISORDER; EVIDENCE BASED MEDICINE; FATIGUE; HUMAN; IMPOTENCE; LIBIDO DISORDER; MALE; MEDICAL DECISION MAKING; MEDICAL EXAMINATION; NOSE CONGESTION; ORTHOSTATIC HYPERTENSION; OUTCOME ASSESSMENT; PATIENT CARE; PATIENT REFERRAL; PERIPHERAL EDEMA; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; REVIEW; SYMPTOMATOLOGY; TUMOR GROWTH; URINARY TRACT DISEASE;

ADRENERGIC ALPHA-ANTAGONISTS; AGED; ALGORITHMS; CHOLESTENONE 5 ALPHA-REDUCTASE; DISEASE PROGRESSION; ENZYME INHIBITORS; FAMILY PRACTICE; HUMANS; MALE; MIDDLE AGED; PROSTATIC HYPERPLASIA; REFERRAL AND CONSULTATION; RISK FACTORS; UROLOGIC DISEASES;

EID: 33751004682     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2006.01194.x     Document Type: Review

References (52)

1. Wei JT, Calhoun E, Jacobsen SJ. Urologic diseases in America project: benign prostatic hyperplasia. J Urol 2005; 173: 1256-61.
2. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human prostatic hyperplasia with age. J Urol 1984; 132: 474-9.
3. Flanigan RC, Reda DJ, Wasson JH et al. 5-year outcome of surgical resection and watchful waiting for men with moderately symptomatic benign prostatic hyperplasia: A Department of Veterans Affairs cooperative study. J Urol 1998; 160: 12-6.
4. Jacobsen SJ, Jacobson DJ, Girman CJ et al. Natural history of prostatism: Risk factors for acute urinary retention. J Urol 1997; 158: 481-7.
5. McConnell JD, Bruskewitz R, Walsh P et al. for The Finasteride Long-Term Efficacy and Safety Study Group. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatitic hyperplasia. N Engl J Med 1998; 338: 557-63.
6. Rhodes T, Girman CJ, Jacobsen SJ et al. Longitudinal prostate growth rates during 5years in randomly selected community men 40 to 70 years old. J Urol 1999; 161: 1174-9.
7. Roberts RO, Jacobsen SJ, Jacobson DJ et al. Longitudinal changes in peak urinary flow rates in a community-based cohort. J Urol 2000; 163: 107-13.
8. Jacobsen SJ, Girman CJ, Guess HA et al. Natural history of prostatism: longitudinal changes in voiding symptoms in community dwelling men. J Urol 1996; 155: 595-600.
9. Sarma AV, Jacobsen SJ, Girman CJ et al. Concomitant longitudinal changes in frequency of and bother from lower urinary tract symptoms in community dwelling men. J Urol 2002; 168: 1446-52.
10. Garraway WM, Russell EB, Lee RJ et al. Impact of previously unrecognized benign prostatic hyperplasia on daily activities of middle-aged and elderly men. Br J Gen Pract 1993; 43: 318-21.
11. AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations. J Urol 2003; 170: 530-47.
12. Roehrborn CG, McConnell JD, Lieber M et al. for the PLESS Study Group. Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. Urology 1999; 53: 473-80.
13. Jacobsen SJ, Girman CJ, Lieber MM. Natural history of benign prostatic hyperplasia. Urology 2001; 58 (Suppl. 6A): 5-16.
14. Arrighi HM, Metter EJ, Guess HA, Fozzard JL. Natural history of benign prostatic hyperplasia and risk of prostatectomy. Urology 1991; 38 (Suppl.): 4-8.
15. Kuritzky L. A primary care physician's perspective on benign prostatic hyperplasia. Rev Urol 2003; 5 (Suppl. 5): S42-S48.
16. Roehrborn CG, McConnell J, Bonilla J et al. for the PROSCAR Long-Term Efficacy and Safety Study. Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. J Urol 2000; 163: 13-20.
17. Chapple CR, Roehrborn CG. A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: Focus on the bladder. Eur Urol 2006; 49: 651-59.
18. Stewart WF, Van Rooyen JB, Cundiff GW et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003; 20: 327-36.
19. Beckman TJ, Mynderse LA. Evaluation and management of benign prostatic hyperplasia. Mayo Clin Proc 2005; 80: 1356-62.
20. Barry MJ, Fowler FJ Jr, O'Leary MP et al. The American Urological Association Symptom Index for benign prostatic hyperplasia. J Urol 1992; 148: 1549-57.
21. Roehrborn CG, Boyle P, Gould AL, Waldstreicher J. Serum prostate-specific antigen as a predictor or prostate volume in men with benign prostatic hyperplasia. Urology 1999; 53: 581-9.
22. Wright EJ, Fang J, Metter EJ et al. Prostate specific antigen predicts the long-term risk of prostate enlargement: Results from the Baltimore Longitudinal Study of Aging. J Urol 2002; 167: 2484-8.
23. Scientific Committee of the First International Consultation on Incontinence. Assessment and treatment of urinary incontinence. Lancet 2000; 355: 2153-8.
24. McNeill SA, Hargreave TB, Geffriaud-Ricouard C, Santoni J, Roehrborn CG. Postvoid residual urine in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: Pooled analysis of eleven controlled studies with alfuzosin. Urology 2001; 57: 459-65.
25. Roehrborn CG. Acute relief or future prevention: Is urology ready for preventive health care? Urology 2000; 56 (Suppl. 5A): 12-9.
26. Downs J, Clearfield M, Weis S et al. for the AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA 1998; 279: 1615-22.
27. Sacks FM, Pfeffer MA, Moye LA et al. for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-9.
28. Shepherd J, Cobbe SM, Ford I et al. for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholestrolemia. N Engl J Med 1995; 333: 1301-7.
29. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-57.
30. Anderson JB, Roehrborn CG, Schalken JA, Emberton M. The progression of benign prostatic hyperplasia: Examining the evidence and determining the risk. Eur Urol 2001; 39: 390-9.
31. Eastell R. Treatment of postmenopausal osteoporosis. N Engl J Med 1998; 338: 736-46.
32. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-86.
33. McConnell JD, Roehrborn CG, Bautista OM et al. for the Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349: 2387-98.
34. Djavan B, Fong YK, Harik M et al. Longitudinal study of men with mild symptoms of bladder outlet obstruction treated with watchful waiting for four years. Urology 2004; 64: 1144-8.
35. Wasson JH, Reda DJ, Bruskewitz RC et al. for the Veterans Affairs Cooperative Study Group on Transurethral Resection of the Prostate. A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. N Engl J Med 1995; 332: 75-9.
36. Boyle P, Roehrborn CG, Harkaway R et al. 5-Alpha reductase inhibition provides superior benefits to alpha blockade by preventing AUR and BPH-related surgery. Eur Urol 2004; 45: 620-7.
37. Bartsch G, Rittmaster RS, Klocker H. Dihydrotestosterone and the concept of 5α-reductase inhibition in human benign prostatic hyperplasia. Eur Urol 2000; 37: 367-80.
38. Ielhé C, Radvanyi F, Gil Diez de Medina S et al. Differences in steroid 5α-reductase iso-enzymes expression between normal and pathological human prostate tissue. J Steroid Biochem Mol Biol 1999; 68: 189-95.
39. Clark RV, Hermann DJ, Hoda G et al. Effective suppression of dihydrotestosterone (DHT) by GI198745, a novel 5 alpha reductase inhibitor. J Urol 1999; 161 (Suppl. 4): 268.
40. Clark RV, Hermann DJ, Cunningham GR et al. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5 α-reductase inhibitor. J Clin Endocrinol Metab 2004; 89: 2179-84.
41. Roehrborn CG, Boyle P, Nickel JC et al. on behalf of the ARIA3001, ARIA3002, and ARIA3003 Study Investigators. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002; 60: 434-41.
42. Roehrborn CG, Marks LS, Fenter T et al. Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia. Urology 2004; 63: 709-15.
43. Andriole G, Bruchovsky N, Chung LWK et al. Dihydrotestosterone and the prostate: The scientific rationale for 5α-reductase inhibitors in the treatment of benign prostatic hyperplasia. J Urol 2004; 172: 1399-403.
44. Kaplan SA. Use of alpha-adrenergic inhibitors in treatment of benign prostatic hyperplasia and implications on sexual functioning. Urology 2004; 63: 428-34.
45. Lepor H, for the Terazosin Research Group. Long-term efficacy and safety of terazosin in patients with benign prostatic hyperplasia. Urology 1995; 45: 406-13.
46. Lepor H, for the Tamsulosin Investigator Group. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Urology 1998; 51: 892-900.
47. Narayan P, Tewari A. A second phase III multicenter placebo controlled study of 2 dosages of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia. J Urol 1998; 160: 1701-6.
48. Roehrborn CG, for the Alfus Study Group. Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: A randomized, placebo-controlled trial. Urology 2001; 58: 953-9.
49. Roehrborn CG. Alfuzosin 10mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: Results of a 2-year placebo-controlled study. BJU Int 2006; 97: 734-41.
50. Baldwin KC, Ginsberg PC, Roehrborn CG, Harkaway RC. Discontinuation of alpha-blockade after initial treatment with finasteride and doxazosin in men with lower urinary tract symptoms and clinical evidence of benign prostatic hyperplasia. Urology 2001; 58: 203-9.
51. Barkin J, Guimarães M, Jacobi G et al. for the SMART-1 Investigator Group. Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with dual 5α-reductase inhibitor dutasteride. Eur Urol 2003; 44: 461-6.
52. Barry MJ, Fowler FJ, Bin L et al. The natural history of patients with benign prostatic hyperplasia as diagnosed by North American urologists. J Urol 1997; 157: 10-4.